Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases.

Company profile
Ticker
FOLD
Exchange
Website
CEO
John Crowley
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMICUS THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
1.Callidus Biopharma, Inc. • 2.Celenex, Inc. • 3.Scioderm, Inc. • 4.MiaMed, Inc. • 5.Amicus Therapeutics International Holding Limited • 6.Amicus Therapeutics UK Limited • 7.Amicus Therapeutics UK Operations Limited • 8.Amicus Therapeutics SAS • 9.Amicus Therapeutics B.V. • 10.Amicus Therapeutics GmbH ...
IRS number
200422823
FOLD stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
9 Jan 23
8-K
Entry into a Material Definitive Agreement
28 Dec 22
8-K
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
16 Dec 22
8-K
Corporate OverviewNovember 2022At the Forefront of Therapies for Rare Diseases
16 Nov 22
8-K
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
7 Nov 22
8-K
Entry into a Material Definitive Agreement
7 Nov 22
424B5
Prospectus supplement for primary offering
7 Nov 22
8-K
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
7 Nov 22
10-Q
2022 Q3
Quarterly report
7 Nov 22
8-K
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
28 Oct 22
Transcripts
FOLD
Earnings call transcript
2022 Q3
7 Nov 22
FOLD
Earnings call transcript
2022 Q2
5 Aug 22
FOLD
Earnings call transcript
2022 Q1
9 May 22
FOLD
Earnings call transcript
2021 Q4
24 Feb 22
FOLD
Earnings call transcript
2021 Q3
9 Nov 21
FOLD
Earnings call transcript
2021 Q2
6 Aug 21
FOLD
Earnings call transcript
2021 Q1
10 May 21
FOLD
Earnings call transcript
2020 Q4
1 Mar 21
FOLD
Earnings call transcript
2020 Q3
5 Nov 20
FOLD
Earnings call transcript
2020 Q2
10 Aug 20
Latest ownership filings
SC 13G
MORGAN STANLEY
8 Feb 23
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
6 Feb 23
4
John F Crowley
3 Feb 23
4
Bradley L Campbell
3 Feb 23
SC 13G/A
BlackRock Inc.
31 Jan 23
4
Ellen Rosenberg
25 Jan 23
4
David Michael Clark
19 Jan 23
4
Daphne Quimi
19 Jan 23
4
MARGARET G MCGLYNN
17 Jan 23
4
Ellen Rosenberg
13 Jan 23
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 281.53 mm | 281.53 mm | 281.53 mm | 281.53 mm | 281.53 mm | 281.53 mm |
Cash burn (monthly) | (no burn) | 8.96 mm | 11.28 mm | 21.40 mm | 3.88 mm | 13.03 mm |
Cash used (since last report) | n/a | 38.99 mm | 49.08 mm | 93.12 mm | 16.86 mm | 56.67 mm |
Cash remaining | n/a | 242.54 mm | 232.46 mm | 188.42 mm | 264.67 mm | 224.86 mm |
Runway (months of cash) | n/a | 27.1 | 20.6 | 8.8 | 68.3 | 17.3 |
Institutional ownership, Q3 2022
98.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 217 |
Opened positions | 33 |
Closed positions | 29 |
Increased positions | 71 |
Reduced positions | 70 |
13F shares | Current |
---|---|
Total value | 3.10 bn |
Total shares | 275.75 mm |
Total puts | 311.10 k |
Total calls | 575.80 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Perceptive Advisors | 27.37 mm | $285.77 mm |
Avoro Capital Advisors | 26.80 mm | $279.79 mm |
Vanguard | 25.87 mm | $270.10 mm |
Redmile | 21.72 mm | $226.75 mm |
BLK Blackrock | 19.90 mm | $207.74 mm |
MS Morgan Stanley | 17.18 mm | $179.40 mm |
JHG Janus Henderson | 14.78 mm | $154.27 mm |
JPM JPMorgan Chase & Co. | 14.34 mm | $149.69 mm |
Palo Alto Investors | 9.85 mm | $102.81 mm |
Wellington Management | 8.06 mm | $84.11 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Feb 23 | Bradley L Campbell | Common Stock | Sell | Dispose S | No | Yes | 12.9754 | 20,000 | 259.51 k | 845,129 |
1 Feb 23 | Bradley L Campbell | Common Stock | Option exercise | Acquire M | No | No | 2.45 | 11,700 | 28.67 k | 865,129 |
1 Feb 23 | Bradley L Campbell | Stock Options Common Stock | Option exercise | Dispose M | No | No | 2.45 | 11,700 | 28.67 k | 42,225 |
1 Feb 23 | John F Crowley | Common Stock | Sell | Dispose S | No | Yes | 13.1102 | 147,316 | 1.93 mm | 1,004,669 |
1 Feb 23 | John F Crowley | Common Stock | Option exercise | Acquire M | No | No | 5.13 | 56,596 | 290.34 k | 1,151,985 |
1 Feb 23 | John F Crowley | Common Stock | Option exercise | Acquire M | No | No | 6.1 | 83,333 | 508.33 k | 1,095,389 |
1 Feb 23 | John F Crowley | Stock Options Common Stock | Option exercise | Dispose M | No | No | 5.13 | 56,596 | 290.34 k | 0 |
1 Feb 23 | John F Crowley | Stock Options Common Stock | Option exercise | Dispose M | No | No | 6.1 | 83,333 | 508.33 k | 0 |
24 Jan 23 | Rosenberg Ellen | Common Stock | Sell | Dispose S | No | Yes | 13.3172 | 31,839 | 424.01 k | 332,345 |
18 Jan 23 | David Michael Clark | Common Stock | Sell | Dispose S | No | Yes | 13.5 | 7,382 | 99.66 k | 241,067 |
Press releases
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
3 Jan 23
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
16 Dec 22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD
15 Nov 22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD
14 Nov 22